- Home
- ZNTL vs MPLN Comparison
ZNTL vs MPLN Comparison
Compare ZNTL & MPLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- MPLN
- Stock Information
- Founded
- ZNTL 2014
- MPLN 1980
- Country
- ZNTL United States
- MPLN United States
- Employees
- ZNTL N/A
- MPLN N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- MPLN Business Services
- Sector
- ZNTL Health Care
- MPLN Consumer Discretionary
- Exchange
- ZNTL Nasdaq
- MPLN Nasdaq
- Market Cap
- ZNTL 238.2M
- MPLN 188.6M
- IPO Year
- ZNTL 2020
- MPLN N/A
- Fundamental
- Price
- ZNTL $3.12
- MPLN $10.89
- Analyst Decision
- ZNTL Buy
- MPLN Hold
- Analyst Count
- ZNTL 7
- MPLN 2
- Target Price
- ZNTL $10.86
- MPLN $25.00
- AVG Volume (30 Days)
- ZNTL 1.2M
- MPLN 75.1K
- Earning Date
- ZNTL 11-04-2024
- MPLN 11-05-2024
- Dividend Yield
- ZNTL N/A
- MPLN N/A
- EPS Growth
- ZNTL N/A
- MPLN N/A
- EPS
- ZNTL N/A
- MPLN N/A
- Revenue
- ZNTL $40,560,000.00
- MPLN $954,923,000.00
- Revenue This Year
- ZNTL N/A
- MPLN N/A
- Revenue Next Year
- ZNTL N/A
- MPLN $0.63
- P/E Ratio
- ZNTL N/A
- MPLN N/A
- Revenue Growth
- ZNTL N/A
- MPLN N/A
- 52 Week Low
- ZNTL $2.83
- MPLN $6.35
- 52 Week High
- ZNTL $18.24
- MPLN $69.20
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.34
- MPLN 55.66
- Support Level
- ZNTL $2.92
- MPLN $9.90
- Resistance Level
- ZNTL $3.23
- MPLN $12.40
- Average True Range (ATR)
- ZNTL 0.17
- MPLN 1.06
- MACD
- ZNTL 0.00
- MPLN 0.26
- Stochastic Oscillator
- ZNTL 38.33
- MPLN 69.14
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About MPLN MultiPlan Corporation
MultiPlan Corp is a provider of data analytics and technology-enabled solutions designed to bring affordability, efficiency, and fairness to the U.S. healthcare industry. The company interprets clients' needs and customizes solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry.